Progenra's discovery platforms are derived from the ubiquitin-proteasome system, a major regulator of cellular functions. The system’s importance has been highlighted by the Nobel Prize awarded to the pioneers in ubiquitin research and validated with bortezomib/Velcade's approval in 2003 and the continuous expansion of Celgene iMids, which are ubiquitin ligase modulators. In the years since, there has been a steady increase in our understanding of the key players in the enzymatic pathways of the ubiquitin proteasome system and their importance in various disease states.
Several of Progenra's scientists and collaborators have been trained in leading ubiquitin laboratories, and they continue to develop first in class breakthrough small molecule drug candidates with in vivo proof of concept. It is clear that ubiquitin is not only a tag for protein degradation, but also a regulator of the cellular location or activity of extant proteins in ways that can be exploited therapeutically. Progenra's scientists are continually incorporating newly uncovered roles for ubiquitin into the company's technology.
Progenra's biology team, coupled with in-house medicinal chemistry and Progenra’s Discovery Network, enable the discovery and development of clinical candidates both internally and with partners, and to that end we maintain active programs in cancer, cardiovascular disease, inflammation, neurodegenerative diseases, and orphan diseases such as cystic fibrosis.